

### **OPEN ACCESS**

EDITED AND REVIEWED BY Paola Patrignani, University of Studies G. d'Annunzio Chieti and Pescara, Italy

\*CORRESPONDENCE
Wilbert Bouwman,

☑ Wilbert.bouwman@philips.com

SPECIALTY SECTION
This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 10 March 2023 ACCEPTED 28 March 2023 PUBLISHED 05 April 2023

#### CITATION

Bouwman W, Verhaegh W and van de Stolpe A (2023), Corrigendum: Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity. *Front. Pharmacol.* 14:1183639. doi: 10.3389/fphar.2023.1183639

# COPYRIGHT © 2023 Bouwman, Verhaegh and van de

Stolpe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity

Wilbert Bouwman\*, Wim Verhaegh and Anja van de Stolpe

Philips Research, Eindhoven, Netherlands

#### KEYWORDS

ulcerative colitis, crohn's disease, IBD, signal transduction pathway, treatment response

## A Corrigendum on

Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity

by Bouwman W, Verhaegh W and van de Stolpe A (2022). Front. Pharmacol. 13:1008976. doi: 10. 3389/fphar.2022.1008976


In the published article, there was an error in Figure 2 as published. In this figure for the prediction and assessment of response to anti-TNF $\alpha$  remission-induction treatment in CD (A) a different TGFbeta pathway model version was used. The corrected Figure 2 and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Bouwman et al. 10.3389/fphar.2023.1183639



## FIGURE 2

Prediction and assessment of response to anti-TNF $\alpha$  remission-induction treatment in CD (A) and UC (B). Datasets GSE16879. STP activity analysis of intestinal mucosa samples for prediction of response to anti-TNF $\alpha$  remission induction treatment in patients with CD and UC. STP PAS before and after remission induction treatment. For details, see Methods. STP PAS are shown for the AR, MAPK, NFxB, TGF $\beta$ , JAK-STAT1/2, JAK-STAT3, and Wnt STPs. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.001, \*\*\*\*p < 0.0001, ns: not significant. For supporting analysis results, see Supplementary Table S1.